(169) Lipid Monitoring Practice for Patients with Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)

Poster Abstract:

Background: Androgen deprivation therapy (ADT) is a foundation of treatment for individuals diagnosed with advanced prostate cancer. The goal of ADT is to achieve castration levels of testosterone, reducing the impact of androgens on cancer growth. While the reduction of testosterone levels is critical in the management of disease, this treatment modality comes with adverse effects. ADT is associated with an increased risk of developing metabolic syndrome. The impact of ADT on cardiovascular health holds significant importance, given that cardiovascular disease stands as the primary cause of death among men with prostate cancer. One of the cardiovascular adverse effects associated with ADT is dyslipidemia. Although the relationship between ADT and dyslipidemia has been well-described, there are not established practice guidelines for routine monitoring of lipids for men with prostate cancer receiving ADT. The current practice and frequency of lipid monitoring for patients with prostate cancer on ADT is not well defined in the literature. This study is a pilot review of current lipid monitoring practices for men with prostate cancer receiving ADT in a single academic health system. The results from this study will be used to develop practice guidelines for the health system.

Objective: This study aims to determine the frequency of lipid monitoring in patients with a diagnosis of prostate cancer receiving androgen deprivation therapy (ADT) in a single academic health center.

Methods: This is a single-center retrospective review of electronic medical records of men with a diagnosis of prostate cancer who have received care at the UC Health Barrett Cancer Center. This study has been approved by the University of Cincinnati IRB. Inclusion criteria include a diagnosis of prostate cancer, age ≥ 18 years, and documentation of androgen deprivation therapy for a minimum of one year. The primary endpoint is to determine the prevalence of documentation of lipid testing for individuals with prostate cancer receiving ADT within 12 months of the date of data collection. Secondary endpoints include documentation of lipid testing within 12 months to 24 months of data collection, peak LDL values in the previous 12 months, and calculated ASCVD risk score for patients aged 40-75 years old. All endpoints will be described with descriptive statistics.

Results: The results of the study are pending.

Discussion: The results of the study are pending.
Disclosure: Ryan Ruehl and Rowena Schwartz have no financial interests that relate to this research.

References (must also be included in final poster): 1. American Cancer Society. Facts & Figures 2023. American Cancer Society. Atlanta, Ga. 2022.
2. NCCN. Prostate Cancer - NCCN Clinical Practice Guidelines in Oncology, National Comprehensive Cancer Network, 7 Aug. 2023
3. Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825-836.
4. Kumar, N., Vasudeva, V., Yadav, S. et al. The impact of androgen deprivation therapy on the lipid profile in patients with prostate carcinoma. Afr J Urol 28, 27 (2022).
5. Levine, Glenn, et al. “Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk.” Circulation, 16 Feb. 2010.
6. “Lipid Disorders in Adults (Cholesterol, Dyslipidemia): Screening.” United States Preventive Services Taskforce, 30 Dec. 2013
7. Grundy, Scott M., et al. “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.” Circulation, vol. 139, no. 25, 2019
8. Matthew R. Smith and others, Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer, The Journal of Clinical Endocrinology & Metabolism, Volume 87, Issue 2, 1 February 2002, Pages 599–603
9. Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol. 1995;154(1):100-104.
10. Kathleen M Sturgeon, Lei Deng, Shirley M Bluethmann, Shouhao Zhou, Daniel M Trifiletti, Changchuan Jiang, Scott P Kelly, Nicholas G Zaorsky, A population-based study of cardiovascular disease mortality risk in US cancer patients, European Heart Journal, Volume 40, Issue 48, 21 December 2019, Pages 3889–3897
11. Roy S, Zaorsky NG, Bagshaw HP, et al. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022;113(2):278-289.